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Fig. 1. Scheme of heart failure progression. Risk factors, such as hypertension, age,
or  other metabolic disorders can cause diastolic and/or systolic left ventricular dys-
function, and ﬁnally heart failure with preserved or reduced ejection fraction. HFpEF,
heart failure with preserved ejection fraction; HFrEF, heart failure with reducedmpact  of  left  ventricular  ejection  fracti
Heart failure (HF) is a complex clinical syndrome, where not
nly heart failure with preserved ejection fraction (HFpEF) but also
eart failure with reduced EF (HFrEF) are substantially involved
1,2]. Indeed, HFpEF and HFrEF respectively account for approx-
mately half of HF patients [3,4]. Although it has been reported
hat the prognosis is comparable between patients with HFpEF and
hose with HFrEF [3,4], we also have previously demonstrated that
he patients with HFpEF had a signiﬁcantly better prognosis than
hose with HFrEF; however, after the adjustment with stage of HF,
he survival became comparable between the 2 groups, suggest-
ng a smaller population of HFpEF in the advanced stage of HF [5].
his previous study also demonstrated that the 5-year survival rate
rom all-cause death was apparently better than in the previous
tudy [6], probably because the patients are monthly followed up
o control sodium intake and blood pressure in Japan. Consistently,
t has been also reported that intensive medical treatment for HF
atients with close follow-up can reduce re-admission for HF and
ardiac deaths [7].
In the current issue of Journal of Cardiology,  Kaneko et al.
dentiﬁed the clinical characteristics, long-term outcomes, and
rognostic factors of HFpEF and HFrEF in a Japanese real-world
linical practice [8]. The major ﬁndings were (1) that the preva-
ence of HFpEF was relatively high, (2) that patients with HFpEF
howed a better prognosis than those with HFrEF; however, the
linical outcomes of HFpEF and HFrEF patients were comparable
n inpatients, and (3) that the independent predictors of all-cause
eath were older age, chronic kidney disease (CKD), anemia, prior
yocardial infarction, absence of statin treatment, and lower left
entricular EF in HFrEF, and lower body mass index, CKD, anemia,
igher B-type natriuretic peptide and left ventricular hypertrophy
n HFpEF [8]. As also previously reported, patients with HFpEF are
onsistently older, with a higher prevalence of females and hyper-
ension, compared to those with HFrEF [4,6,9]. Furthermore, it has
een also reported that the prognostic factors of HF are older age,
everity of HF, anemia, presence of CKD, lower EF, and the pres-
nce of pulmonary hypertension due to left heart disease [8,10–12].
ased on these observational ﬁndings, more effective treatment for
F should be developed in the near future.
The mechanism of interaction between HFpEF and HFrEF
hould also be clariﬁed in future studies. As previously reported,
everal risk factors, such as metabolic disorders and hypertension,
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are related to HF [13], which can cause left ventricular diastolic
and/or systolic dysfunction, and then symptomatic HFpEF or
HFrEF may  occur (Fig. 1). However, in the clinical situation, we
often experience the improvement or worsening of EF during the
observational period, indicating that left ventricular EF is variable
and suggesting that HFpEF and HFrEF are not persistent. From this
point of view, some factors other than left ventricular EF might be
important for the prognosis. This issue should also be clariﬁed in
the near future.
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